In addition, prior work from our laboratory demonstrated that signaling through CXCR1/2 receptors expressed in carcinoma cells enables their acquisition of mesenchymal tumor features which, in turn, can drive resistance to EGFR-targeted therapy in lung cancer models [7] or immune-mediated lysis in models of breast cancer [8]. This evidence concerns the gene CXCR1 and carcinoma.